Whole‐genome sequencing has uncovered over 300 gene mutations in DLBCL,7 especially driver mutations initiating lymphomagenesis and promoting chemoimmunotherapy resistance, including chromosome translocation‐induced overexpression of oncogenes (BCL2, c‐Myc or BCL6),8 nuclear factor‐kappa B (NF‐κB) signalling pathway activation by CARD11, MyD88 CD79A/B mutations,9 or epigenetic reprogramming by EZH2, MLL2 and CREBBP mutations.10 This evidence concerns the gene MYC and diffuse large B-cell lymphoma.